Clinical Trial Update: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of Letetresgene autoleucel engineered T cells targeting NY-ESO-1 in advanced non-small cell lung cancer has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Letetresgene Autoleucel (letetresgene autoleucel)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2021-09-05